Delving into the Latest Updates on Trilaciclib Dihydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Trilaciclib, Trilaciclib hydrochloride, G1T 28

+ [4]

Target

CDK4 x CDK6

Action

inhibitors

Mechanism

CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors)

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesRespiratory Diseases+ [1]

Active Indication

Extensive stage Small Cell Lung CancerChemotherapy-induced myelosuppressionSmall cell lung cancer limited stage+ [4]

Inactive Indication

Colorectal CancerMetastatic Colorectal CarcinomaMetastatic Neoplasm to the Bladder+ [4]

Originator Organization

G1 Therapeutics, Inc.

Active Organization

Patheon Manufacturing Services LLC

Simcere Pharmaceutical Group Ltd.

G1 Therapeutics, Inc.

+ [3]

Inactive Organization-

License Organization

Quantumleap Healthcare Collaborative

Pharmacosmos Therapeutics Inc.

Simcere Pharmaceutical Co., Ltd.

+ [2]

Drug Highest PhaseApproved

First Approval Date

United States (12 Feb 2021),

Chemotherapy-induced myelosuppression

RegulationBreakthrough Therapy (United States), Priority Review (China), Conditional marketing approval (China), Fast Track (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC24H32Cl2N8O

InChIKeyBRCYOXKEDFAUSA-UHFFFAOYSA-N

CAS Registry1977495-97-8

Triple negative breast cancer (TNBC) has attracted much attention due to its young age of onset, high aggressiveness, lack of clear therapeutic targets and poor clinical prognosis.Eribulin is a novel non-taxane anti-microtubule inhibitor with unique microtubule and non-microtubule anti-tumor mechanism.Myelosuppression is the cause of many cancer chemotherapy-related adverse events, such as infections, sepsis, bleeding, and fatigue, resulting in delayed hospital stays or the need for treatment with hematopoietic growth factors, blood transfusions, and more.In addition, myelosuppression usually leads to a lower dose or longer interval of chemotherapy, which reduces the intensity of chemotherapy and affects the benefit of chemotherapy for patients.Trilaciclib is a highly potent, selective and reversible CDK4/6 inhibitor that protects bone marrow by protecting hematopoietic stem cells and progenitor cells (HSPCs) during systemic chemotherapy.

Start Date04 Nov 2026

Sponsor / Collaborator

Sun Yat-Sen University

NCT07473128

/ Not yet recruitingPhase 3

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer

The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is:
Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer?
Participants will be randomised to receive either trilaciclib or placebo.

Start Date31 Mar 2026

Sponsor / Collaborator

Pharmacosmos A/S

ChiCTR2600117016

/ Not yet recruitingNot ApplicableIIT

Evaluating the Efficacy and Safety of Trilaciclib in Patients Receiving First-line Sintilimab Plus Chemotherapy for Advanced Driver Gene-negative Non-squamous Non-Small Cell Lung Cancer

Start Date31 Jan 2026

Sponsor / Collaborator

Sheng Jing Hospital

100 Clinical Results associated with Trilaciclib Dihydrochloride

Login to view more data

100 Translational Medicine associated with Trilaciclib Dihydrochloride

Login to view more data

100 Patents (Medical) associated with Trilaciclib Dihydrochloride

Login to view more data

91

Literatures (Medical) associated with Trilaciclib Dihydrochloride

01 Nov 2025·Cell Reports Medicine

Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy

Article

Author: Yue, Ping ; Zuo, Duo ; Tian, Xiangdong ; Liu, Zhiyong ; Gao, Yuan ; Guo, Hua ; Liu, Wei ; Ling, Aomei ; Chen, Liwei ; Wang, Chengmeng ; Luo, Yi ; Zuo, Ran ; He, Yuchao ; Feng, Yuanying ; Gong, Wenchen ; Chen, Peng ; Wang, Yu

Immunotherapy-based combination approaches have improved treatment efficacy in advanced non-small cell lung cancer (NSCLC), but progressive disease remains a challenge. Trilaciclib is a cyclin-dependent kinase 4/6 inhibitor approved for myelopreservation in extensive-stage small cell lung cancer (ES-SCLC). Our results demonstrate that trilaciclib has antitumor potential in NSCLC without significant toxicity. It reprograms the tumor immune microenvironment by primarily increasing antitumor neutrophils and CD8⁺ T cells. Trilaciclib induces tumor cell senescence and the senescence-associated secretory phenotype in a cGAS-STING-dependent manner, which further facilitates the infiltration and activation of CD177⁺ neutrophils with anti-tumor properties. These neutrophils enhance CD8⁺ effector T cell activation and promote antitumor immunity. Additionally, activated CD8⁺ T cells recruit and activate neutrophils, forming a positive feedback loop. Combining trilaciclib with anti-PD-1 antibodies presents a promising strategy for NSCLC treatment.

02 Sep 2025·Immunotherapy

The value and safety of trilaciclib in combination with first-line chemotherapy and immunotherapy for extensive-stage SCLC

Article

Author: Xiao, Li ; He, Shuo ; Zhou, Yingnan ; Lu, Hongling ; Sun, Yunchuan ; Yin, Xiaoming ; Zhang, Shengtan ; Zhou, Jixnxi

AIMS:

To evaluate the myeloprotective effects, safety, and survival outcomes of trilaciclib in first-line chemotherapy for extensive-stage small cell lung cancer (ES-SCLC) in China.

METHODS:

A single-center, retrospective study was conducted with 120 ES-SCLC patients receiving chemotherapy plus immunotherapy between January 2020 and January 2024. Patients were divided into a trilaciclib group (n = 60) and a control group (n = 60). The groups were compared for chemotherapy-related adverse effects, efficacy (ORR, DCR), and survival (PFS, OS).

RESULTS:

Trilaciclib significantly reduced the incidence of grade 3-4 neutropenia (18.3% vs. 66.7%, p < 0.001), grade ≥ 3 anemia (13.3% vs. 33.3%, p = 0.010), and thrombocytopenia (10.0% vs. 26.7%, p = 0.018). Median PFS was significantly longer in the trilaciclib group (6.2 vs. 4.7 months, p = 0.0139, HR = 0.6238, 95%CI 0.4474-0.9826), but no significant difference was observed in OS (15.6 vs. 13.8 months, p = 0.2399, HR = 0.8053, 95%CI 0.5577-1.163). The ORR was similar between the two groups (73.3% vs. 63.3%, p = 0.239).

CONCLUSIONS:

Trilaciclib demonstrates myeloprotective benefits in first-line treatment of ES-SCLC, with significant reductions in chemotherapy-related myelosuppression and improvements in treatment adherence. Although PFS was improved, no significant differences in OS or ORR were observed, indicating the need for further research with larger sample sizes to confirm its clinical efficacy.

01 Sep 2025·Translational Lung Cancer Research

Myelopreservation effect of trilaciclib in extensive-stage small cell lung cancer (ES-SCLC): a systematic review and meta-analysis with trial sequential analysis of randomized clinical trials

Article

Author: Cao, Shiyi ; Ding, Yiling ; Chen, Jing ; Shu, Yamin ; Deng, Zhijie ; Chu, Qian ; Yuan, Xun

Background:

Small cell lung cancer (SCLC) patients undergoing chemotherapy often suffer from myelosuppression, which not only increases disease burden but also significantly impairs quality of life. A novel medication, trilaciclib, has been designed to mitigate myelosuppression and protect patients from its debilitating effects. Although trilaciclib has shown promising myeloprotection ability, researchers are seeking more evidence to gain substantial insights into its efficacy and safety profile, given the limited trial results and small sample sizes. Therefore, this study pools the efficacy and safety results of existing randomized controlled trials (RCTs) through meta-analysis and assesses the reliability of findings using trial sequential analysis (TSA).

Methods:

Studies were searched in databases including PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov. Only RCTs with extensive-stage SCLC (ES-SCLC) patients receiving trilaciclib were included, with placebo as the comparator group. Risk of Bias 2 tools were applied to evaluate the risk of bias of included studies. Meta-analysis was conducted for result synthesis with TSA to assess the robustness of results.

Results:

With predetermined search terms, a total of 135 studies and trials were screened, and eventually four trials were included in analysis with low risks of bias. Of the total 356 randomized patients from four trials, 195 received trilaciclib and 161 received placebo. The results indicated that trilaciclib could significantly reduce the occurrence of severe neutropenia (SN) [odds ratio (OR): 0.08; 95% confidence interval (CI): 0.04 to 0.15], shorten the duration of SN (DSN) in cycle 1 [mean difference (MD): -3.19; 95% CI: -3.96 to -2.42] and reduce the occurrence of febrile neutropenia (FN) (OR: 0.22; 95% CI: 0.08 to 0.59).

Conclusions:

Our meta-analysis with TSA provided robust evidence that trilaciclib could significantly protect ES-SCLC patients receiving chemotherapies from myelosuppression, thereby enabling more consistent treatment administration and potentially enhancing clinical outcomes. However, more studies are necessary to clarify indirect outcomes.

180

News (Medical) associated with Trilaciclib Dihydrochloride

31 Mar 2026

·ir.nextcure.com

NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026

The American Society for Clinical Oncology to be held in Chicago May 29 – June 2, 2026 BELTSVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company, today announced that an abstract for SIM0505 has been accepted for the American Society for Clinical Oncology (ASCO 2026) meeting being held May 29 – June 2 in Chicago, Illinois. SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The ongoing open-label, Phase 1 study (NCT06792552) is evaluating SIM0505 in advanced solid tumors, including ovarian cancer, with an emphasis on platinum resistant ovarian cancer. About SIM0505 SIM0505 is a novel antibody drug conjugate (ADC) directed to cadherin-6 (CDH6 ADC), featuring a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The ADC is designed for broad anti-tumor activity, fast systemic clearance and an improved potential therapeutic window. SIM0505 is being evaluated in an open-label, Phase 1 study (NCT06792552) for the potential treatment of advanced solid tumors, including ovarian cancer, with an emphasis on platinum resistant ovarian cancer. NextCure holds exclusive global rights for SIM0505, excluding China, Hong Kong, Macau, and Taiwan which are retained by Simcere Zaiming Pharmaceutical Co., Ltd. About NextCure, Inc. NextCure is a clinical-stage biopharmaceutical company focused on advancing innovative medicines to treat cancer patients through the use of targeted therapies including antibody-drug conjugates. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells within and beyond the tumor microenvironment, and the role each interaction plays in a biologic response. About Simcere Zaiming Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, "Simcere"). Founded in 2023, Simcere Zaiming is dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including Enzeshu®, COSELA®, Enweida®, Endostar®, and Enlituo®. The Company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners. Forward-Looking Statements Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to funding for our operations, objectives and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our therapies. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “should”, “due”, “estimate”, “expect”, “intend”, “hope”, “may”, “objective”, “plan”, “predict”, “potential”, “positioned”, “seek”, “target”, “towards”, “forward”, “later”, “will”, “would”, and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: market and other conditions; positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure’s limited operating history and not having any products approved for commercial sale; NextCure’s history of significant losses; NextCure’s need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; NextCure’s reliance upon collaborators and international vendors for advancing clinical programs; NextCure’s ability to maintain listing of its common stock on the Nasdaq Global Select Market; and NextCure’s dependence on key personnel. More detailed information on these and additional factors that could affect NextCure’s actual results are described under the heading “Risk Factors” in NextCure’s most recent Annual Report on Form 10-K and in NextCure’s other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change. Investor Inquiries Timothy Mayer, Ph.D. NextCure, Inc. Chief Operating Officer (240) 762-6486 IR@nextcure.com Mike Moyer Managing Director, LifeSci Advisors, LLC Phone: (617) 308-4306 mmoyer@lifesciadvisors.com Source: NextCure

Phase 1ASCOADC

21 Mar 2026

·www.einpresswire.com

Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer

March 17, 2026 -- Pharmacosmos today announced the initiation of a phase III, randomised, double-blind, placebo-controlled, multicentre clinical trial evaluating the efficacy and safety of trilaciclib in participants with limited-stage small cell lung cancer. The study is being conducted at clinical sites in the United States, EU and the United Kingdom. The trial will compare trilaciclib with placebo when administered prior to standard chemoradiotherapy and is designed to assess whether trilaciclib can reduce chemotherapy-induced myelosuppression and improve treatment tolerability in patients with limited-stage small cell lung cancer. Trilaciclib is currently approved and marketed in the United States for use prior to platinum/etoposide-containing or topotecan-containing regimens in adults with extensive-stage small cell lung cancer, where it is indicated to decrease the incidence of chemotherapy-induced myelosuppression. Limited-stage small cell lung cancer represents an earlier stage of the disease, in which the cancer is confined to one side of the chest and treatment is typically delivered with curative intent using concurrent chemotherapy and radiation (chemoradiotherapy). As with extensive-stage disease, treatment of limited-stage disease is associated with chemotherapy-induced myelosuppression, which can lead to dose reductions, treatment delays and an increased risk of complications. Chemotherapy-induced myelosuppression is traditionally managed once it occurs. The study evaluates a novel approach in which bone marrow protection is administered prior to chemotherapy. Trilaciclib is a short-acting CDK4/6 inhibitor administered intravenously prior to chemotherapy. By transiently inducing cell-cycle arrest in haematopoietic stem and progenitor cells, trilaciclib is designed to protect all blood cell lineages from chemotherapy-induced damage. “With this phase III study, we are extending the clinical development of trilaciclib into limited-stage small cell lung cancer,” said Lars Lykke Thomsen, Executive Vice President and Chief Medical Officer at Pharmacosmos. “We look forward to evaluating the role of bone marrow protection with trilaciclib in patients with limited-stage small cell lung cancer receiving intensive chemoradiotherapy.” Pharmacosmos has submitted regulatory applications for trilaciclib in extensive-stage small cell lung cancer outside the United States. The phase III study is a randomised, double-blind, placebo-controlled, multicentre trial conducted in the United States, EU and the United Kingdom evaluating trilaciclib administered prior to standard chemoradiotherapy in participants with limited-stage small cell lung cancer. The study will assess efficacy and safety endpoints related to chemotherapy-induced myelosuppression and overall treatment tolerability. Trilaciclib is an intravenous CDK4/6 inhibitor designed to be administered prior to chemotherapy to protect bone marrow function. It is approved in the United States for use in adults receiving a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer. Pharmacosmos A/S is a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anaemia. Building on our foundational expertise in carbohydrate chemistry and cell cycle biology, we develop innovative treatments for unmet patient needs, with a focus on iron metabolism and blood-related disorders. Founded in 1965 and headquartered in Denmark, our team is made up of more than 700 specialists across the UK, Ireland, the Nordics, Germany, Canada, the USA, and China. The content above comes from the network. if any infringement, please contact us to modify.

Drug ApprovalClinical Result

22 Dec 2025

·www.fiercebiotech.com

Ipsen continues ADC push with $1B deal for Simcere\'s preclinical LRRC15-targeting asset

As part of a new deal between Ipsen and Simcere, upfront, development, regulatory and commercial milestone payments could potentially total $1.06 billion.\n Ipsen may be a recent entrant into the antibody-drug conjugate space, but the French biopharma is continuing to make up for lost time.The latest addition to the Paris-based company’s portfolio is SIM0613, an ADC from Simcere Zaiming that targets leucine-rich repeat-containing 15 (LRRC15). The protein is highly expressed on a range of tumor types and cancer-associated fibroblasts, meaning SIM0613 should in theory be able to release its cytotoxic payload on these specific sites without damaging healthy cells.The therapy has demonstrated “robust tumor regressions in multiple in vivo preclinical models,” according to this morning’s release. Ipsen is eyeing the launch of SIM0613’s first phase 1 trial in the second half of next year.In return for the exclusive rights to the drug outside China, Ipsen has signed a deal where upfront, development, regulatory and commercial milestone payments could potentially total $1.06 billion. However, the companies didn’t offer a breakdown of the financials.Ipsen only dived into the ADC arena in April 2024 via a $75 million cash and equity investment for Sutro Biopharma’s ROR1-directed STRO-003. Ipsen later decided not to take STRO-003 forward, but, in the meantime, the company secured a Topo1 inhibitor via a deal with Foreseen Biotechnology.“Today’s announcement underscores our bold vision to lead innovation and shape the future of oncology,” Ipsen’s head of R&D Christelle Huguet, Ph.D., said in the Dec. 22 release.“By advancing first- and best-in-class therapies early, we maximize the potential to transform patient outcomes globally,” Huguet said. “The addition of the SIM0613 ADC is testament to this ambition—pioneering science that opens new possibilities for those who need it most and builds on Ipsen’s rapidly evolving research and early development portfolio, with over 20 programs added since 2020.” Simcere’s CEO Renhong Tang, Ph.D., said the company is “excited to partner with Ipsen on this novel drug candidate and look forward to working together to advance the clinical development of SIM0613.”Simcere already markets several oncology drugs in China, including the FDA-approved Cosela to ease the harmful effects of chemotherapy as well as the biliary tract cancer treatment Enweida.Simcere’s clinical-stage pipeline has been in demand in 2025, with AbbVie kicking off the year by securing a trispecific antibody from the company in a $1 billion biobucks deal. The candidate, dubbed SIM0500, targets GPRC5D, BCMA and CD3 and was already in phase 1 trials for multiple myeloma in the U.S. and China.Five months later, Nextcure continued its own ADC pivot by penning a $745 million deal for the ex-China rights to Simcere’s phase 1-stage CDH6-targeted therapy.

Phase 1ADCLicense out/in

100 Deals associated with Trilaciclib Dihydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11987	Trilaciclib Dihydrochloride	L01XE	DB15442

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Extensive stage Small Cell Lung Cancer	China	G1 Therapeutics, Inc.	12 Jul 2022
Chemotherapy-induced myelosuppression	United States	Pharmacosmos A/S	12 Feb 2021

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Small cell lung cancer limited stage	Phase 3	-	Pharmacosmos A/S	31 Mar 2026
Triple Negative Breast Cancer	Phase 3	China	Simcere Pharmaceutical Group Ltd.	01 Jun 2023
Metastatic Triple-Negative Breast Carcinoma	Phase 3	United States	G1 Therapeutics, Inc.	14 May 2021
Metastatic Triple-Negative Breast Carcinoma	Phase 3	China	G1 Therapeutics, Inc.	14 May 2021
Metastatic Triple-Negative Breast Carcinoma	Phase 3	Australia	G1 Therapeutics, Inc.	14 May 2021
Metastatic Triple-Negative Breast Carcinoma	Phase 3	Bulgaria	G1 Therapeutics, Inc.	14 May 2021
Metastatic Triple-Negative Breast Carcinoma	Phase 3	France	G1 Therapeutics, Inc.	14 May 2021
Metastatic Triple-Negative Breast Carcinoma	Phase 3	Moldova	G1 Therapeutics, Inc.	14 May 2021
Metastatic Triple-Negative Breast Carcinoma	Phase 3	Poland	G1 Therapeutics, Inc.	14 May 2021
Metastatic Triple-Negative Breast Carcinoma	Phase 3	Russia	G1 Therapeutics, Inc.	14 May 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO_GI2026	Phase 2	Oesophageal squamous cell carcinoma recurrent First line	10	Carboplatin (AUC=4-6, IV, Q3W)Paclitaxel (175 mg/m2, IV, Q3W)Trilaciclib (240 mg/m2, IV, Q3W) + Carboplatin (AUC=4-6, IV, Q3W)Paclitaxel (175 mg/m2, IV, Q3W)Trilaciclib (240 mg/m2, IV, Q3W) + Carboplatin (AUC=4-6, IV, Q3W)Paclitaxel (175 mg/m2, IV, Q3W)Trilaciclib (240 mg/m2, IV, Q3W) + Carboplatin (AUC=4-6, IV, Q3W)Paclitaxel (175 mg/m2, IV, Q3W)Trilaciclib (240 mg/m2, IV, Q3W) (Metastatic/recurrent esophageal squamous cell carcinoma)	zcwmsrjcta(jamcvqjoro) = Other AEs were mainly grade 1-2, including decreased appetite (50%), fatigue (40%), headache (40%), and alopecia (10%). vcangirxab (qjmcgcemdi ) View more	Positive	08 Jan 2026
NCT06955156 (ESMO2025)	Phase 2	Advanced Triple-Negative Breast Carcinoma Neoadjuvant	28	Trilaciclib (240mg/m) + anti-PD-1-antibody + nab-paclitaxel + carboplatin	cepviddqtt(sbxumrxlab) = xirrsudiel kpangsvfwb (adbplbkysz ) View more	Positive	17 Oct 2025
ChiCTR2500097520 (ESMO2025)	Phase 2	stomach adenocarcinoma \| Gastroesophageal junction adenocarcinoma Adjuvant \| First line	115	Trilaciclib (Cohort 1)	tfyfhbpswu(hjhcgjdwcs) = Trilaciclib-related adverse events were limited to 2 cases of phlebitis, with no new safety signals owepntoiis (khprrmgcrw )	Positive	17 Oct 2025
				Trilaciclib (Cohort 2)
NCT06698965 (ESMO2025)	Phase 2	Small Cell Lung Cancer	19	Trilaciclib + Etoposide + Carboplatin + Envafolimab	teeiuyoatd(crhxfhgkma) = zajashvgjv aljsjnxdkm (qtywjlrzth ) View more	Positive	17 Oct 2025
				Etoposide + Carboplatin + Envafolimab	teeiuyoatd(crhxfhgkma) = muqbfggrfy aljsjnxdkm (qtywjlrzth ) View more
NCT05978648 (ESMO2025)	Phase 2	Early Stage Breast Carcinoma Adjuvant HR-negative \| HER2- positive	89	Epirubicin/cyclophosphamide followed by weekly paclitaxel+Trilaciclib (Triple-negative breast cancer (TNBC))	pzuznqfqcx(osezdtmcgk) = bvzjgtlnks ckfhbgoswo (bpxayvlzoa ) View more	Positive	17 Oct 2025
				Docetaxel/carboplatin/trastuzumab ± pertuzumab+Trilaciclib (HER2-positive breast cancer)	pzuznqfqcx(osezdtmcgk) = rwdsqmkcda ckfhbgoswo (bpxayvlzoa ) View more
NCT04887831 (PRESERVE3, CTgov)	Phase 2	Bone Marrow Diseases \| Neutropenia \| Urothelial Carcinoma of the Urinary Bladder ... View more	92	Avelumab+Carboplatin+Gemcitabine+cisplatin (Platinum-based Chemotherapy Followed by Avelumab Maintenance Therapy)	golylonjuz = rpnzbkckcd ohtkkxcmgu (phfmhuyxlq, lkgunobgzb - ojdzmppugz) View more	-	17 Aug 2025
				Avelumab+Carboplatin+Trilaciclib+Gemcitabine+cisplatin (Trilaciclib Plus Platinum-based Chemotherapy Followed by Avelumab Maintenance Therapy)	golylonjuz = owzgzhklku ohtkkxcmgu (phfmhuyxlq, nukylkfmsn - rsrfuxyrsh) View more
NCT05910034 (ASCO2025)	Phase 2	Non-Small Cell Lung Cancer Second line PD-1 inhibitors	25	Trilaciclib+Envafolimab+Docetaxel	arwahkqeff(qryldguikl) = Hematological toxicity occurred in 17/25 (68%) pts during the first cycle, with a lower incidence in cohort A compared to cohorts B and C ngwphycqmp (fikcyzzhev ) View more	Positive	30 May 2025
				Docetaxel+Envafolimab
AACR2025	Not Applicable	Extensive stage Small Cell Lung Cancer	201	Trilaciclib 240 mg/m^2 + Chemotherapy	dszxumbmtm(xqfiknfiyv) = ytdqnhhwwe gytogdikwm (lvuomrhrxm ) View more	Positive	30 Apr 2025
NCT05113966 (ASCENT, CTgov)	Phase 2	Triple Negative Breast Cancer \| Metastatic Triple-Negative Breast Carcinoma	30	Trilaciclib+Sacituzumab govitecan-hziy	kcgozrlygg(fhxvjbylay) = auxvzfxjih pqrgculzzn (mtcaigkskr, aoamroysnx - jcmogwajst) View more	-	29 Jan 2025
NCT04607668 (PRESERVE 1, Pubmed \| JNCI Cancer Spectr)	Phase 3	Metastatic Colorectal Carcinoma Maintenance	-	Trilaciclib	lvgyerxmkx(vvmvmzqwbh) = Grade 3/4 adverse events, including neutropenia, diarrhea, and leukopenia, were less frequent with trilaciclib vs placebo (64.8% vs 73.1%) ixocmjxmzi (njipibecvm )	Negative	03 Jan 2025
				Placebo